Kalaris Therapeutics Inc
KLRS
View Detailed Chart
5.522USD
-0.298-5.13%
Market hours （ET）Quotes delayed by 15 min
16.61MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-5.13%
5 Days
-15.96%
1 Month
-47.21%
6 Months
-13.04%
Year to Date
-34.58%
1 Year
-35.79%
View Detailed Chart
TradingKey Stock Score of Kalaris Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Kalaris Therapeutics Inc's fundamentals are relatively very healthy, with low ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 126 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kalaris Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Kalaris Therapeutics Inc Highlights
StrengthsRisks
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Undervalued
The company’s latest PE is -1.89, at a low 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 292.79K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
19.000
Target Price
+226.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Kalaris Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Kalaris Therapeutics Inc Info
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Ticker SymbolKLRS
CompanyKalaris Therapeutics Inc
CEOOxtoby (Andrew)
Websitehttps://kalaristx.com/
Related Instruments
+1.45%
-0.64%
+0.75%
+2.98%
-0.74%
+1.67%
+0.21%
+0.46%
+0.49%
-0.60%
+2.03%
+0.11%
+0.76%
+2.12%
+1.60%
0.00%
+0.18%
-0.43%
+2.12%
+1.45%Popular Symbols
246.500
-2.300 (-0.92%)
167.965
+0.445 (+0.27%)
67654.640
+1070.590 (+1.61%)
259.889
-15.451 (-5.61%)
2068.320
+68.320 (+3.42%)
364.080
+2.250 (+0.62%)
4537.920
+45.400 (+1.01%)
101.732
+1.123 (+1.12%)
1.145
-0.006 (-0.48%)
159.593
-0.659 (-0.41%)
